ADC Therapeutics (ADCT) Soars 23.81% on Upcoming Data Catalysts

ADC Therapeutics (ADCT) surged 23.81% today, marking its second consecutive day of gains, with a total increase of 38.46% over the past two days. The share price reached its highest level since December 2024, with an intraday decline of NaN%.

The strategy of buying ADCT shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 4.61% annualized gain. However, the overall performance was slightly underwhelming, with a 5-year compound annual growth rate (CAGR) of 1.78% compared to the S&P 500's CAGR of 6.15%. This suggests that while the strategy provided some stability, it may not have fully capitalized on broader market gains.

ADC Therapeutics is gearing up for several data catalysts related to ZYNLONTA combinations, aiming to achieve significant regulatory milestones throughout 2025. These developments are expected to drive future growth and foster positive investor sentiment.

In addition to the upcoming data catalysts, analysts have been upgrading their ratings for ADC Therapeutics following the company's latest results. This positive outlook from analysts further supports the stock's recent performance and indicates a bullish sentiment towards the company's future prospects.